S&P 500

5.321,41

0,25%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
BioCardia Inc (BCDA)
BioCardia Inc (BCDA) Notícias

BCDA

BioCardia (BCDA)

BioCardia Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:BCDA

1 2 3 4 5 6 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
21/05/2024	18:00	GlobeNewswire Inc.	BioCardia Announces Reverse Stock Split	NASDAQ:BCDA	BioCardia Inc
14/05/2024	17:02	GlobeNewswire Inc.	BioCardia Reports First Quarter 2024 Business Highlights and Financial Results	NASDAQ:BCDA	BioCardia Inc
01/05/2024	08:00	GlobeNewswire Inc.	BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes	NASDAQ:BCDA	BioCardia Inc
25/04/2024	10:00	GlobeNewswire Inc.	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	NASDAQ:BCDA	BioCardia Inc
27/03/2024	17:00	GlobeNewswire Inc.	BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	NASDAQ:BCDA	BioCardia Inc
20/03/2024	08:00	GlobeNewswire Inc.	BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	NASDAQ:BCDA	BioCardia Inc
13/03/2024	08:00	GlobeNewswire Inc.	BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	NASDAQ:BCDA	BioCardia Inc
12/03/2024	08:00	GlobeNewswire Inc.	BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	NASDAQ:BCDA	BioCardia Inc
04/03/2024	10:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BCDA	BioCardia Inc
04/03/2024	10:00	GlobeNewswire Inc.	BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	NASDAQ:BCDA	BioCardia Inc
27/02/2024	18:53	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:BCDA	BioCardia Inc
15/02/2024	09:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BCDA	BioCardia Inc
14/02/2024	19:06	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:BCDA	BioCardia Inc
14/02/2024	18:17	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:BCDA	BioCardia Inc
08/02/2024	09:00	GlobeNewswire Inc.	BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	NASDAQ:BCDA	BioCardia Inc
31/01/2024	09:00	GlobeNewswire Inc.	BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference	NASDAQ:BCDA	BioCardia Inc
03/01/2024	09:00	GlobeNewswire Inc.	BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders	NASDAQ:BCDA	BioCardia Inc
19/12/2023	09:00	GlobeNewswire Inc.	BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	NASDAQ:BCDA	BioCardia Inc
18/12/2023	09:16	GlobeNewswire Inc.	BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes	NASDAQ:BCDA	BioCardia Inc
06/12/2023	08:03	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:BCDA	BioCardia Inc
06/12/2023	02:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:BCDA	BioCardia Inc
05/12/2023	18:11	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:BCDA	BioCardia Inc
29/11/2023	09:00	GlobeNewswire Inc.	BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval	NASDAQ:BCDA	BioCardia Inc
16/11/2023	14:56	GlobeNewswire Inc.	BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules	NASDAQ:BCDA	BioCardia Inc
14/11/2023	09:15	GlobeNewswire Inc.	BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure	NASDAQ:BCDA	BioCardia Inc
08/11/2023	18:11	GlobeNewswire Inc.	BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results	NASDAQ:BCDA	BioCardia Inc
08/11/2023	18:06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:BCDA	BioCardia Inc
01/11/2023	18:04	GlobeNewswire Inc.	BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023	NASDAQ:BCDA	BioCardia Inc
19/10/2023	18:00	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:BCDA	BioCardia Inc
11/10/2023	07:00	GlobeNewswire Inc.	BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II	NASDAQ:BCDA	BioCardia Inc